Clinical Trial Update: Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension [Phase 4]

View source ↗

Summary

Phase 4 trial update on an aliskiren-based treatment algorithm showing efficacy and tolerability in patients with mild to moderate essential hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Aliskiren-based treatment algorithm (aliskiren)

Snippet

Sponsor: Novartis | Conditions: Essential Hypertension ( Mild to Moderate) | Phase 4 | Status: COMPLETED | Results posted: 2011-01-11